TrialNature medicine2024

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.

Javier Cortés et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.